Table 3 Clinical variables of benign and malignant VCFs in the training and test groups
Clinical variable | Training (n = 100) | Test (n = 44) | ||||
|---|---|---|---|---|---|---|
Benign (n = 47) | Malignant (n = 53) | p Value* | Benign (n = 20) | Malignant (n = 24) | P Value | |
SULpeak | 2.79 ± 0.90† | 5.72 ± 2.73 | < 0.001 | 2.73 ± 1.02 | 5.46 ± 3.08 | < 0.001 |
SULmax | 3.45 ± 1.12 | 7.35 ± 3.59 | < 0.001 | 3.36 ± 1.15 | 7.16 ± 4.05 | < 0.001 |
SUVpeak | 3.58 ± 1.08 | 7.37 ± 3.50 | < 0.001 | 3.43 ± 1.27 | 6.92 ± 3.90 | < 0.001 |
SUVmax | 4.43 ± 1.35 | 9.46 ± 4.51 | < 0.001 | 4.23 ± 1.45 | 9.08 ± 5.08 | < 0.001 |
Age, year | 71.68 ± 9.29 | 59.89 ± 14.40 | < 0.001 | 69.00 ± 8.74 | 62.25 ± 11.76 | 0.04 |
Osteolytic destruction | < 0.001 | 0.003 | ||||
No | 39 (82.98)‡ | 14 (26.42) | 18 (90.00) | 10 (41.67) | ||
Yes | 8 (17.02) | 39 (73.58) | 2 (10.00) | 14 (58.33) | ||
Fracture line | < 0.001 | 0.025 | ||||
No | 29 (61.70) | 51 (96.23) | 13 (65.00) | 23 (95.83) | ||
Yes | 18 (38.30) | 2 (3.77) | 7 (35.00) | 1 (4.17) | ||
Soft tissue mass/swelling | 0.097 | 0.974 | ||||
No | 35 (74.47) | 30 (56.60) | 16 (80.00) | 18 (75.00) | ||
Yes | 12 (25.53) | 23 (43.40) | 4 (20.00) | 6 (25.00) | ||
Appendices/posterior vertebrae involvement | < 0.001 | 0.034 | ||||
No | 38 (80.85) | 15 (28.30) | 17 (85.00) | 12 (50.00) | ||
Yes | 9 (9.15) | 38 (71.70) | 3 (15.00) | 12 (50.00) | ||